Skip navigation
Home
Menu
Menu
Study
Student life
Research and innovation
Global
About us
Staff
Students
Search the site
Centre of Excellence for Long-acting Therapeutics
Menu
About us
LONGEVITY
HALo
Nanotherapeutics Hub
Teoreler
PKRxiv
LAPaL
Blog
News
Events
Contact us
News
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degener
01 November 2024
Long-Acting Degradable Implants for Endometriosis Treatment
01 November 2024
First-ever long-acting injectable for malaria prevention administered to study volunteer
01 November 2024
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema\n
04 October 2024
UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers
04 October 2024
Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lena
20 September 2024
GSK present data at ERS for depemokimab an asthma medication that last 6 months.
13 September 2024
First Patients Dosed in Debiopharm's Phase III Trial of a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty
13 September 2024
Innovative semaglutide hydrogel could reduce diabetes shots to once a month\n
13 September 2024
Newer stories
Older Stories